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Abstract Many missense variants in BRCA1 are of
unclear clinical significance. Functional and genetic
approaches have been proposed for elucidating the clinical
significance of such variants. The purpose of this study was
to evaluate BRCA1 missense variants for their effect on
both homologous recombination (HR) and non homolo-
gous end joining (NHEJ). HR frequency evaluation:
HeLaG1 cells, containing a stably integrated plasmid that
allows us to measure HR events by gene conversion events,
were transfected with the pcDNA3b expression vector
containing the BRCA1-wild-type (BRCA1 wild type) or the
BRCA1-unclassified variants (BRCA1-UCVs). The NHEJ
was measured by a random plasmid integration assay. The
assays suggested a BRCA1 involvement mainly in the
NHEJ. As a matter of fact, the Y179C and the A1789T
variant significantly altered the NHEJ activity as compared
to the wild type, suggesting that they may be related to
BRCA1-associated pathogenicity by affecting this func-
tion. The variants N550H and I1766S, and the mutation
M1775R did not alter the NHEJ frequency. These data,
besides proposing a method for the study of BRCA1
variants’ effect on HR and NHEJ, highlighted the need for
a range of functional assays to be performed to identify
variants with altered function.
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Introduction
Breast cancer is the most common neoplasia in women,
and the second cause of death after cardiovascular diseases
in the Western world. About 10% of breast cancer cases is
inheritable, and about 40% of those is caused by mutations
in BRCA1 or BRCA2 genes.
BRCA1 is a tumor suppressor gene, which encodes a
nuclear protein involved in several cellular processes
including DNA double strand break repair by homologous
recombination (HR) and non homologous end joining
(NHEJ), cell cycle control, apoptosis, and maintenance of
the genomic stability [1–3]. BRCA1 gene is highly poly-
morphic. Nonsense or frameshift BRCA1 mutations
encoding truncated, but not functional proteins, predispose
women to early-onset breast and ovarian cancer. However,
several missense variants of uncertain pathological signif-
icance have been identified.
A variety of predictive approaches have been reported to
distinguish cancer-related variants from neutral polymor-
phisms. These methods are based on the degree of con-
servation among species, the nature and position of amino
acid substitution, the analysis of co-segregation pattern of
the variant with disease in affected family members, the
inactivation of the wild-type allele either by loss of het-
erozygosity or by promoter hypermethylation in the tumor
[4–6]. Moreover, several functional assays biologically
evaluating the variant effect on the ability of the protein to
perform some of the key cellular functions are currently
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used. They can potentially be used to predict whether the
variant predisposes to disease or alternatively has no sig-
nificant influence on cancer risk [7].
In this study, we used two functional assays in HeLa
cells, which specifically evaluate the effect of the over-
expression of the wild-type or mutated BRCA1 on spon-
taneous HR and on random chromosomal integration of a
linearized plasmid DNA, a subtype of non HR, to better
elucidate the clinical relevance of some BRCA1 unclassi-
fied variants.
There are several evidences of BRCA1 involvement in
DNA double strand break repair by HR. BRCA1 colocal-
izes with RAD51 protein into sub-nuclear complexes in
mitotic cells, and clinical mutations at the C-terminal
BRCA1 BRCT domain disrupt the nuclear foci localization
[2]. Moreover, BRCA1-deficient cells are highly sensitive
to ionizing radiation and display chromosome instability
[8]. BRCA1-/- mouse embryonic stem cells have impaired
HR [9]. On the other hand, even though BRCA1 binds in
vitro and in vivo to Mre11//Rad50/Nbs1 complex [10], its
role in NHEJ pathway has not yet been completely clari-
fied. As a matter of fact, the frequency of random plasmid
integration in transiently BRCA1 wild type transfected
HCC1937 cells is significantly increased as compared to
the parental cell line [11], whereas this phenomenon is also
impaired in BRCA1-/- mouse embryonic fibroblasts, but
contradictory results were obtained [10, 12, 13].
In this study, we selected some missense variants from a
mutational screening of 276 breast and/or ovarian cancer
families. Four non-synonymous variants, which localized
in different BRCA1 functional domains, were identified as
potentially deleterious and likely disrupting the gene
function using three predictive software: SIFT, Polyphen,
and Align-GVGD. These variants were the Y179C, the
N550H, the I1766S, and the A1789T. One known missense
variant (M1775R), previously reported as deleterious
mutation, was chosen as positive control. We evaluated the
effect of the over-expression of the wild-type or these
mutated BRCA1 proteins on spontaneous HR and NHEJ
events in HeLa cells.
Materials and methods
Samples and mutation selection
The DNA samples from 276 individuals, belonging to 276
breast and/or ovarian cancer families, collected at the
University Hospital of Pisa, were analyzed for BRCA1 and
BRCA2 germline mutations using an automated DNA
sequencer (ABI 3100; Applera-Applied Biosystems). We
used the following selection criteria:
(1) occurrence of two or more cases of breast and/or
ovarian cancer in first or second degree relatives;
(2) early onset of the disease;
(3) occurrence of bilateral breast cancer or occurrence of
breast and ovarian cancer in the same individual.
The screening revealed several known as well as novel
unclassified variants (UCVs) localized across all the
BRCA1 gene sequence. To identify non-synonymous
amino acid changes likely to disrupt BRCA1 gene function,
three comparative evolutionary bioinformatic programs
were used: sorting intolerant from tolerant (SIFT) [14].
http://blocks.fhcrc.org/sift/SIFT.html), polymorphism phe-
notyping (PolyPhen) [15]; http://tux.embl-heidelberg.de/
ramensky/pilyphen.cgi and Align-GVGD (http://agvgd.
iarc.fr/alignments) [16].
Plasmids
To determine whether the expression of BRCA1-wild-type
or mutated, affects homologous and non-homologous
recombination in human cells, we used pcDNA3–BRCA1
expression plasmid (a gift from David Livingston, Boston
MA, USA) [2]. In this vector, the b-globin gene was
inserted to optimize the expression of BRCA1 [2]. To
express the BRCA1 missense variant Y179C, N550H,
A1789T, and I1766S and the pathogenic control M1775R,
we constructed the corresponding pcDNA3–BRCA1
derivative vector by site-specific mutagenesis using the
QuikChange II XL Site-Directed Mutagenesis Kit (Strata-
gene Inc) following the protocol recommended by the
manufacturer. To measure the effect of the expression of
BRCA1 wild type or mutated on random plasmid integra-
tion, we used the plasmid pBlue-puro (a kind gift from
Roland Kanaar, Erasmus University, Rotterdam, NL) that
contains the puromycin resistance gene driven by cyto-
megalovirus promoter.
Cell culture and transfection
HeLaG1 and HeLa cell lines were routinely cultured in
Dulbecco’s modified Eagle’s medium, DMEM (GIBCO),
supplemented with 10% (v/v) fetal calf serum, 100 units/ml
penicillin, and 100 mg/ml streptomycin (GIBCO). Cultures
were incubated at 37C in 5% CO2 and 95% relative
humidity. Transfections were performed using Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s
protocol. The efficiency of transfection was determined
using the pGFP plasmid (a gift from Giuseppe Rainaldi,
Pisa Italy) followed by direct count of GFP positive cells
by FACS analysis (Becton–Dickinson Biosciences). Usu-
ally, the efficiency of transfection ranged from 70 to 85%.
Breast Cancer Res Treat
123
Immunoblotting
Twenty-four hours after transfection of pcDNA3BRCA1,
aliquots of 4 9 105 cells were washed twice in phosphate
buffered saline (PBS) 19 and lysed in the Laemmli sample
buffer 19 (Tris–HCl 50 Mm pH 6.8, SDS 2%, glycerol
10%, bromophenol blue 0.1%, b-mercaptoethanol
100 mM) together with the Protease Inhibitor Cocktail 19
(Sigma). The protein extracts were denaturated at 100C
for 5 min. A total of *120 lg of whole cell extract was
subjected to electrophoresis at 10–20 mA for *3 h in 6%
SDS-polyacrylamide gel; thereafter, the proteins were
transferred to polyvinylidene fluoride membrane at
170 mA for 17 h at 4C using a Mini-PROTEAN Cell
apparatus (Bio-Rad). BRCA1 was detected using anti-
BRCA1 monoclonal antibody Ab4 (Calbiochem, Gibbs-
town, NJ) diluted 1:100 with 3% of BSA. This antibody
recognizes aa 1005–1313 in the exon 11 of the BRCA1
protein. Anti-mouse horseradish peroxidase-linked anti-
body (Amersham Biosciences, Piscataway, NJ), diluted
1:15,000, was used as a secondary antibody. The BRCA1
protein was detected using the ECL chemioluminescence
solution (Bio-Rad), and the signals were developed on
photographic films (Sigma).
Homologous recombination assay
The HeLaG1 cells (a gift from Margherita Bignami, Rome
Italy) contain a stably integrated plasmid that allows to
measure gene conversion events between two differentially
mutated hygromycin-resistance (HygR) genes [17]. One
HygR gene is mutated at the PvuI site (hyg1), and the other
HygR at the SacII site (hyg2) (Fig. 3). An intrachromosomal
recombination event leads the restoration of wt HygR gene;
therefore, the frequency of intrachromosomal recombination
was calculated as total number of HygR clones 9 10-5 viable
cells. HeLaG1 cells were transfected with the pcDNA3b
expression vector containing the wild-type BRCA1 or the
BRCA1–UCVs. 24 h after transfection, cells were harvested
and plated [6 9 105 cells/10-cm dish and 102 cells/6-cm dish,
for plating efficiency (PE) evaluation]. For the selection of the
recombination events, 24 h later, we added hygromicin
0.2 mg/ml (Sigma) to the medium. Medium was changed
twice and, after 10–15 days, plates were stained with crystal
violet, and clones were counted [18].
Random plasmid integration assay
The effect of BRCA1 expression on NHEJ was determined,
as previously reported, by testing the effect of these proteins
on random plasmid integration in HeLa cells [19]. The
frequency of NHEJ was determined by co-transfecting the
HeLa cells with 2 lg of the pcDNA3b. BRCA1 wild type or
BRCA1-UCV vectors and 2 lg of pBlue-puro that carries no
homology with the genome of HeLa cells so that it stably
integrates by non-homologous recombination [19]. One day
after transfection, cells were collected and plated (2 9 105
cells/dish) in 10-cm dishes containing 0.2 lg/ml puromy-
cin. Culture medium was changed after 7 days and replaced
with puromycin-free fresh medium. The colonies were
stained and counted 7 days later, and the frequency of
recombination was calculated by dividing the number of
puromycin-resistant colonies by the number of seeded cells
corrected by the plating efficiency.
Statistical analysis
The frequency of HygR clones obtained after the trans-
fection of the empty-vector was used as reference. The
results were analyzed by the t-Student test. All the analyses
were performed using Statgraphics (StatPoint Inc. USA).
Results
Variants selection
We selected four non-synonymous UCVs, suggested by
SIFT, Polyphen, and Align-GVGD software, as likely
capable of disrupting the protein function: the Y179C, the
N550H, the I1766S, and the A1789T (Table 1, Fig. 1)
identified in 4 out of 276 breast and breast-ovarian cancer
families.
The M1775R, classified as deleterious, was used as
positive control [20]. The A1789T variant has never been
described previously. It was found in one family. The
proband was affected by breast cancer at 32 years of age.
The mother of the proband, affected by breast and ovarian
cancer diagnosed at 46 and 50 years of age, respectively,
was found to be a carrier of the variant (Fig. 2a). The
I1766S was classified as a deleterious amino acidic change
by Carvalho et al. [21]. It was found in one family, and the
proband had ovarian carcinoma diagnosed at 42 years of
age. A DNA sample was available from a sister of the
proband unaffected at 50 years of age. She tested negative
for the mutation (Fig. 2b).
The Y179C was classified as neutral by Judkins [22]. The
N550H was classified as probably neutral by Tavtigian [16].
These two UCVs were inherited together with the poly-
morphism F486L in two apparently unrelated families
(Fig. 2c). The proband from one family was affected by
breast cancer at 42 years of age. Two-second-degree rela-
tives in the paternal branch, the proband’s grandmother and
a cousin, were affected by breast cancer. The affected
cousin was found negative for the variants. The proband
from the other family was affected by bilateral metacronous
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breast cancer at 48 and 53 years of age. The proband’s
mother and two cousins were affected by breast cancer.
Unfortunately none of them was available for mutation
testing.
Functional assays
Homologous recombination in HeLa cells
In order to set up a novel functional assay to distinguish
between neutral polymorphisms and deleterious mutations,
we created several vectors derived from pcDNA3b-BRCA1
wild type, by site-directed mutagenesis, each of them
expressing a selected UCV. These vectors were transfected
in the HeLaG1 cells that carry a recombination substrate
measuring intrachromosomal recombination events
between the mutated hyg1 and hyg2 alleles (see ‘‘Materials
and methods,’’ Fig. 3). First, we checked whether the
expression of the wild-type and mutated BRCA1 was
detectable 24 h after transfection. Then, we prepared the
total lysate, as described in the methods, and carried out
Western blot analysis. The Fig. 4 shows that all the pro-
teins were expressed roughly at similar level as compared
to the a-tubulin, suggesting that the proteins are equally
stable in the cells. Importantly, the transgene expression
was clearly detectable in the blot after few minutes of
exposure, when the endogenous BRCA1 was not visible
(Fig. 4). The expression of endogenous BRCA1 was seen
only after 2 h of exposure (data not shown). Thus, under
these conditions, we concluded that the exogenous BRCA1
proteins were over-expressed. This prompted us to
determine whether this transient expression of the BRCA1
protein affected recombination. For this reason, 24 h after
transfection, the cells were seeded in the presence of
hygromicin to score for intrachromosomal recombinants.
Under these conditions, the wild type increased the
recombination frequency of 1.6-fold compared to the
empty vector, and this difference was statistically signifi-
cant (t-test P \ 0.005) (Table 2): the HR frequency of
HeLa G1 cells transfected with empty vector was
5.99 ± 2.3 9 10-5 viable cells. All the UCVs tested
showed an increase in HR ranging from 0.98- to 1.3-fold
compared to the empty vector. Thus, a functional assay
based on HR in human cells would not presumably be
helpful to characterize BRCA1 UCVs.
Random plasmid integration in HeLa cells
To evaluate whether BRCA1 UCVs had an influence on
NHEJ, we determined the effects of the expressions of these
proteins on random (non-homologous) plasmid integration
in HeLa cells. The plasmid expressing the BRCA1 wild type
or BRCA1 UCVs was co-transfected with the pBlue-puro
plasmid; after 24 h, the puromycin was added, and the
frequency of random plasmid integration was measured as
number of puromycin-resistant clones on 103 viable cells.
The expression of exogenous wild-type and the mutant
I1766S BRCA1 protein increased the plasmid random
integration in HeLa by 2.3- and 2.5-fold respectively as
compared to the control (Table 2). The over-expressions of
the mutant BRCA1 protein N550H and the M1775R
stimulated the plasmid random integration by 3.1- and 3.2-
fold, respectively, as compared to the control (Table 2).
Table 1 Description of the BRCA2 missense variants analyzed
aBRCA1-UCV bBRCA1-UCV HGVS cFamilies harboring the UCV dBIC recorded (no. of times)
Y179C p.Tyr179Cys 2 54
N550H p.Asn550His 2 54
I1766S p.Ile1766Ser 1 7
A1789T p.Ala1789Thr 1 0
a The UCV nomenclature as in BIC database (http://research.nhgri.nih.gov/bic)
b The UCV nomenclature following the journal guidelines (www.hgvs.org/mutnomen)
c The number of the families harboring the UCV
d Number of probands recorded in the BIC database
Fig. 1 Localization of the
UCVs in the BRCA1 cDNA
sequence. The numbers indicate
the exons. * Mutation localized
in BRCT domain,
# pathogenetic control variant
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The over-expression of variants Y179C and A1789T
induced the highest increase of plasmid random integration
by 3.5- and 4.6-fold respectively as compared to the control
(P B 0.001). In conclusion, the I1766S and the M1775R
UCVs behaved similarly to the BRCA1 wild type, whereas
the Y179C and the A1789T induced a significant increase
of random integration (Table 3).
Discussion
Only a very small fraction of BRCA1 missense variants
have been classified either as deleterious or neutral, while
the majority remain as unclassified variants significance
(UCVs). Interpreting such variants poses significant chal-
lenges for both clinicians and patients. To predict the
clinical relevance of unclassified variants, several approa-
ches are recommended. Bioinformatic prediction software
supported by functional assays, classical genetic analysis
and tumor phenotype, are useful to produce a prediction
algorithm as proposed by Golgdar and Tavtigian [23, 24].
However, in general, it is easier to conclude that a variant
is non-pathogenic than pathogenic [25].
BRCA1 acts as a tumor suppressor gene, and germ-line
mutations which disrupt its functions culminate, after the
loss of the wild-type allele, in cancer development.
Fig. 2 Pedigrees of families
harboring the variants: A1789T
(a), I1766S (b), and Y179C and
N550H (c)
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Although its precise biochemical functions, relevant for
tumor suppression, still remains to be clarified, BRCA1 has
been demonstrated to play a role in several cellular pro-
cesses including DNA double strand breaks repair, tran-
scriptional regulation, chromatin remodelling, cell–cycle
checkpoint control, protein ubiquitination, and centrosome
replication [26].
Several functional assays have been used to distinguish
between BRCA1 cancer-related mutations and neutral
polymorphisms, but due to its multitasking characteristic,
there is no comprehensive functional assay available for
BRCA1 [6, 27]. In this article, we propose two functional
assays: the first one based on transient expression of the
UCVs in HeLa G1 cells containing a HR substrate, and the
second one on random chromosomal integration of a lin-
earized plasmid DNA in the genome of HeLa cells tran-
siently expressing the UCVs. We studied a total of five
BRCA1 missense variants of which one was already clas-
sified as pathogenic and used as a control. The variants
were tested for their effects on both HR and NHEJ. The HR
assay consists in the evaluation of the frequency of HygR
clones due to the cell’s ability to reconstitute the wild-type
Hyg gene that is located, in two mutated copies, in the
vector pTPSN stably integrated in the cell genome.
The NHEJ assay consists in the evaluation of the fre-
quency of puromycin-resistant clones due to random
chromosomal integration of a plasmid DNA containing the
puromycin-resistance gene (Fig. 3).
As shown in our experimental conditions, BRCA1 wild
type increases the HR frequency. Moreover, none of the
BRCA1-UCVs altered the HR frequency when compared
Fig. 3 The intrachromosomal recombination in human cells.
HeLaG1 cells contain two copies of HygR genes inactivated by
10-bp insertions, either at a unique PvuI site (hyg1) or at a unique SacII
site (hyg2); the two mutated hyg genes are in direct repeat orientation
and are separated by a sequence containing the amino-glycoside
phosphotransferase (Neo) gene conferring resistance to G418; an
intrachromosomal recombination event occurring by gene conversion
between the two hyg sequences results in restoration of one of the
mutant hyg genes to wild type; the intrachromosomal deletion of
the DNA sequence between the two mutated hyg genes leads to the
formation of a HygR wild type (Hyg WT) with loss of intervening
sequence; the intrachromosomal recombination was measured after
transfecting HeLaG1 cells with either BRCA1 wild type or UCVs
Fig. 4 Western blot analysis to measure the expression of the BRCA1
wild type and UCVs protein in a HeLa cell line extract. The
monoclonal Ab-4 antibody specifically directed towards exon 11
BRCA1 protein was used, as well as the polyclonal anti-b-tubulin
control antibody. 1 pcDNA3.1, 2 pcDNA3–BRCA1 wt, 3 pcDNA3–
BRCA1-M1775R, 4 pcDNA3–BRCA-A1789T, 5 pcDNA3–BRCA1-
I1766S, 6 pcDNA3–BRCA1Y179C, and 7 pcDNA3–BRCA1-N550H
Table 2 Effect of the expression of wild-type or mutated BRCA1 on
spontaneous intrachromosomal recombination and random plasmid
integration in HeLa cells
Protein
expressed
aIntrachromosomal
recombination HygR clone/105
viable cells
bRandom integration
PuroR clones/103 viable
cells
Control 5.99 ± 2.3 (96) [1] 0.9 ± 0.3 (265) [1]
Wild type 9.1 ± 3.8 (159) [1.6]* 2.1 ± 0.8 (533)[2.3]**
Y179C 6.53 ± 2.3 (78) [1.1] 3.2 ± 1.1 (749) [3.5]***
N550H 7.4 ± 3.2 (90) [1.3] 2.8 ± 1.5 (697)[3.1]*
I1766S 5.80 ± 2.66 (63) [1.03] 2.3 ± 1.2 (625)[2.5]*
M1775R 5.7 ± 1.35 (105) [0.98] 3.0 ± 1.5 (648)[3.2]**
A1789T 7.97 ± 3.7 (150) [1.3] 4.2 ± 1.4 (789)[4.6]***
a Intrachromosomal recombination was determined in HeLa G1 cells
after transient expression of BRCA1
b The random integration was assessed in HeLa cells after co-trans-
fection of the BRCA1 plasmid and the pBlu-puro plasmid
The results are reported as mean of six experiments ± standard
deviation. The numbers in the round brackets represent the total
number of the counted clones. In the square brackets, we show the
fold increase over the control. The control is the empty vector. Results
are statistically analyzed with the Student t-test
*P B 0.05; **P B 0.01; ***P B 0.001
Table 3 Comparison of effects BRCA1 wild type and UCVs on
several recombination-based functional assays
Mutated protein HR in yeast HR in HeLa RI in HeLa
Y179C ? - ?
N550H - - -
I1766S ? - -
M1775R ? - -
A1789T - - ?
The results with reference to homologous recombination in yeast are
reported in Caligo et al. [30]. RI random integration. The variant is
scored as ? when the results obtained are statistically different from
the wt, and as - when the results are not different from the wt
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to the BRCA1 wild type. As a matter of fact, the low
increase in HR frequency obtained when the BRCA1 wild
type was over-expressed, even if statistically significant,
could not be biologically relevant. A twofold increase in
HR frequency has been proposed as cut-off value to be
considered as biologically relevant [28, 29]. In our exper-
iments, no BRCA1 missense variant increased HR by
twofold; therefore, we can conclude that this assay does not
distinguish between pathogenic mutation and neutral
polymorphism. Recently, we have developed a yeast-
recombination assay that could be helpful to characterize
BRCA1 missense variants [30]. In yeast, the over-expres-
sion of pathogenic BRCA1 variants induce HR by twofold
to fourfold as compared to the wild-type or neutral poly-
morphism [30] (Table 3). Thus, the yeast, Saccharomyces
cerevisiae, assay is able to distinguish the pathogenic from
the neutral BRCA1 missense variants. So far, we could not
exactly understand this different effect of the BRCA1
variants on yeast HR as compared to HeLa cells (Table 3);
the ratio between NHEJ and HR varies greatly across
phylogenetic groups. Yeast relies heavily on HR, while in
mammals and plants, NHEJ is the preferred pathway. The
choice may be dictated by genome composition. In large
repetitive genomes of plants and animals, overly efficient
HR may lead to deleterious genomic rearrangements, such
that NHEJ may be a safer choice [31]. This is the main
reason why we measured the effect of BRCA1 missense
variants on NHEJ in a plasmid random integration assay.
Notably, BRCA1 was shown to be involved also in the
regulation of random integration by NHEJ, even when the
molecular mechanism has not been fully understood [32].
Different kinds of assays support this involvement such as
in vitro reconstitution of a linearized plasmid, in vivo
overall end-joining and microhomology mediated end-
joining [12, 33].
The results of this study confirmed a clear involvement of
BRCA1 in random chromosomal integration of a linearized
plasmid DNA. The over-expression of BRCA1-Y179C and
BRCA1-A1789T UCVs increased the frequency of random
integration as compared to the wild type. It was observed that
the over-expression of BRCA1-Y179C induces a hyper-
recombination phenotype also in yeast (Table 3) [30].
Moreover, we have previously reported that the in vivo
analysis on tumor tissue revealed that the proband carrier
of the Y179C showed loss of heterozigosity (LoH) of the
wild-type allele, and the proband carrier of A1789T showed
hypermethylation of the wild-type allele. Both LoH and
hypermethylation are considered to be indicative of the
pathogenicity of the variant [30].
The UCVs, I1766S and N550H, did not affect the NHEJ
frequency, as well as the pathogenetic control M1775R,
suggesting that their roles are not related to the NHEJ
pathway. However, both the I1766S and the mutation
M1775R affected the transcriptional activation ability of
BRCA1 both in yeast and mammalian cells [21]. The
A1789T variant also, in addition to its effect in the NHEJ
assay, appeared to abrogate the BRCA1 transcriptional
activity (L. Guidugli unpublished result), suggesting its
potentially pathogenic characteristic.
These findings suggest that the BRCA1 protein may
have completely independent functions related to specific
protein regions. In terms of defining the influence of UCVs
on BRCA1 function, these findings indicate that all UCVs
should be analyzed by all the functional methods available.
If only one assay is used, then it is possible that a UCV that
inactivates a different function of BRCA1 might be iden-
tified as having no clinical relevance.
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